Ankvita, by IBKR. Why i invested.

AI Summary

Bullish long-term thesis on ImmunityBio (IBRX) based on its FDA-approved NK-cell immune activator Anktiva and multi-cancer opportunity.

IBRX — LONG The author invested in ImmunityBio because Anktiva is a first-in-class FDA-approved NK-cell immune activator already in clinical use, sitting on a known biological pathway rather than theory. The addressable opportunity spans multiple cancer types, and other companies entering the space validate the mechanism while IBRX retains first-mover advantage with approval. The author frames this as a long-term position where medical fundamentals may be ahead of market awareness, not a short-term trade.

IBRX is first with an FDA-approved NK-cell immune activator already in clinical use. Most oncology biotechs never get this far.

Score 4

Comments 14

▶ Full Post Text

Ideas

u/GenFokoff Reddit r/wallstreetbets

Long IBRX on Anktiva approval and multi-cancer opportunity

The author invested in ImmunityBio because Anktiva is a first-in-class FDA-approved NK-cell immune activator already in clinical use, sitting on a known biological pathway rather than theory. The addressable opportunity spans multiple cancer types, and other companies entering the space validate the mechanism while IBRX retains first-mover advantage with approval. The author frames this as a long-term position where medical fundamentals may be ahead of market awareness, not a short-term trade.

▶ Full Post Text

Ideas

More from Reddit — r/wallstreetbets